We are delighted to be joined by our new US Endocrinology Editorial Board member, Donna Ryan, to discuss the latest projects for the American Association of Diabetes Educators and her hopes for the society for 2019.
Filmed at the American Diabetes Association (ADA) annual meeting 2019, San Francisco, USA
1. How would you describe the role of a diabetes educator? (0:05)
2. What projects are the American Association of Diabetes Educators (AADE) working on at the moment? (0:57)
3. Could you tell us a little about the AADE’s work on diversity and improving access and health equity for people with diabetes? (3:40)
4. What is diabetes self management education and what evidence supports its benefits? (4:53)
5. What are you most looking forward to at this year’s ADA annual meeting? (7:21)
Donna Ryan has no conflicts of interest to declare in relation to this video.
touchENDO.com is an independent information resource supporting physicians, clinicians and leading industry professionals in continuously developing their knowledge, effectiveness and productivity, via free-to-access content in multimedia formats.
Share this Video
Related Videos In Diabetes
Andrew Boulton, IDF 2021 – Anticipated congress highlights
It was a pleasure to meet with IDF President, Prof. Andrew Boulton (University of Manchester, UK) ahead of this year’s virtual meeting to discuss anticipated congress highlights and the relationship between COVID-19 and diabetes. Questions What do you expect to be the highlights of this year’s IDF Congress? (0:20-1:30) What have we learned about the […]
Welcome to the IDF Virtual Congress 2021
Programme Chair Prof. João Filipe Raposo introduces the programme for the International Diabetes Federation (IDF) Virtual Congress 2021 (December 6-11) focusing on diabetes complications and the links between COVID-19 and diabetes. https://www.idf2021.org
Matthew Budoff, ENDO 2021: Findings from a Substudy of the VERTIS CV Trial – Ertugliflozin for T2DM & ASCVD
We caught up with Professor Matthew Budoff (UCLA and Lundquist Institute, Torrance, CA, US) to discuss ertugliflozin in patients with type 2 diabetes mellitus and established atherosclerotic cardiovascular disease inadequately controlled with metformin and sulfonylurea (Clinical Trial Identifier: NCT01986881). ‘Efficacy and Safety of Ertugliflozin in Patients With Type 2 Diabetes Mellitus and Established Cardiovascular Disease […]
Journal articles and more to your inbox
Get the latest clinical insights from touchENDOCRINOLOGYSign me up!